Adult Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

The global adult vaccine market is expected to reach an estimated $25.9 billion by 2031 with a CAGR of 6.1% from 2025 to 2031. The major drivers for this market are the growing cases of contagious diseases and supportive government initiatives to spread awareness about the importance of vaccination among the population.

The future of the global adult vaccine market looks promising with opportunities in the private healthcare firm and government hospital markets.

• Within the vaccine type category, multivalent is expected to witness higher growth over the forecast period due to its broader application to protect against bacterial and viral illnesses.
• Within the end use category, private healthcare firm is expected to witness a higher growth over the forecast period.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to presence of strong government support for immunization programs and existence of robust healthcare infrastructure in the region.

Emerging Trends in the Adult Vaccine Market

The emerging trends in the adult vaccine market are indicative of technological evolution, changing public health priorities, and new areas of regulation. These trends are impacting the market and influencing how adult vaccination will evolve in the future.

• RNA Vaccine Technology: The use of mRNA technology is being extended beyond COVID-19 vaccines to other diseases suitable for mRNA vaccinations. Quick approval and high efficacy rates are being sought for these vaccines. This technology enables better control over emerging health situations, such as epidemics, and improves vaccine efficacy.
• Increased Focus on Chronic Disease Prevention: Growing attention is being given to vaccines for chronic illnesses, such as shingles and respiratory diseases. Targeted vaccination for these conditions is being recognized as an inexpensive and effective means to improve well-being and reduce the economic burden associated with chronic diseases.
• Integration of Digital Health Tools: Mobile applications and electronic health records are being integrated with vaccination programs. Digital health tools help in collecting vaccination data, setting reminders, and increasing patient involvement, which makes vaccination campaigns more effective.
• Global Vaccine Access and Equity: There is growing momentum to improve global vaccine uptake, ensure better vaccine distribution, and reduce mortality and morbidity due to disparities in vaccine access. Strategies to deliver vaccines to populations in developing and middle-income countries are crucial for health and pandemic preparedness efforts.
• Personalized Vaccination Approaches: New developments in vaccination focus on applying genetics and other health parameters to individualize vaccination. Mastering the development of vaccines tailored for specific populations or individuals can improve efficacy and safety, thus enhancing vaccination programs.

These emerging trends are reshaping the adult vaccine landscape by driving transformations in technology, increasing the prevention of chronic diseases, utilizing digital health tools, improving vaccine availability, and adopting personalized approaches. These factors are improving vaccine efficiency, acceptability, and the overall health status of the population.

Recent Developments in the Adult Vaccine Market

Recent developments in the adult vaccine market highlight the introduction of new vaccination technologies, changes in vaccination approaches, and increased funding for relevant healthcare interventions. These developments are shaping the market and altering its prospects.

• Advancement in RNA Vaccines: The successful deployment of mRNA technology for COVID-19 vaccines has propelled research into mRNA applications for other diseases. This technology offers rapid production and effective vaccines, thus changing the landscape of vaccine technology and improving the fight against emerging health challenges.
• Expansion of Vaccine Indications: Vaccines are being licensed for wider use. For instance, shingles and influenza vaccines are being reformulated for new populations or offered for other indications as awareness of adult immunization increases.
• Increased Investment in Vaccine Research: Numerous vaccine research, development, and innovation initiatives are receiving funding support, fostering creativity in the industry. Research on developing novel vaccines and improving existing ones is being funded by both corporations and governments, accelerating developments in this field.
• Enhanced Vaccine Distribution Networks: Improvements in vaccine distribution networks are increasing access to vaccines and expanding coverage. Investments in infrastructure, logistics, and supply chains are facilitating the provision of vaccinations to many populations, including those in hard-to-reach areas.
• Strengthened Public Health Campaigns: Public health campaigns are receiving more attention, focusing on adult vaccination. Campaigns emphasizing education, awareness, and vaccination compliance are growing, with greater emphasis on voluntary health measures.

These developments are advancing the adult vaccine market by enhancing vaccine technology, expanding vaccine indications, increasing funding, strengthening distribution networks, and having a greater impact on public health efforts. These factors contribute to better and more effective vaccination programs.

Strategic Growth Opportunities for the Adult Vaccine Market

Factors generating strategic growth opportunities in the adult vaccine market stem from changing population health needs, the availability of new technologies, and shifts in policies. Understanding these factors can enhance market inclusion and organizational growth.

• Expansion into Chronic Disease Vaccines: Growth opportunities are emerging with the development of vaccines for chronic diseases like shingles, pneumococcal disease, and hepatitis B. Effective vaccines for these conditions can reduce the healthcare burden and associated costs, creating a promising market for expansion.
• Integration with Digital Health Solutions: The integration of vaccines with digital health solutions, such as mobile apps and electronic health records, presents a growth opportunity. These tools improve tracking, reminders, and patient engagement, which increases the effectiveness of vaccination programs.
• Focus on Emerging Markets: There is a significant growth opportunity in emerging markets, which face large healthcare gaps and are increasingly accepting of vaccines. Tailoring vaccine products and strategies for these regions can enhance global market reach.
• The Importance of Advances in Vaccines for the Individual: Financing vaccination based on an individual’s health status and genetic data offers a pathway for personalized, successful vaccination. Personalized vaccination approaches can improve patient outcomes and tap into new market segments.
• The Need for Strengthening Vaccine Supply and Administration Systems: Understanding and improving vaccine supply chains and distribution systems is crucial for growth. Better management of logistics, infrastructure, and cold-chain requirements can enhance vaccine supply and market penetration.

These growth opportunities highlight areas for expansion in the adult vaccine market. Companies can leverage these opportunities by focusing on chronic disease vaccines, digital health solutions, emerging markets, and personalized medicine, and improving supply chains.

Adult Vaccine Market Drivers and Challenges

The factors driving or hindering activities in the adult vaccine market include technological developments, economic characteristics, and regulatory frameworks. These factors are key to entering and expanding in the market.

The factors responsible for driving the adult vaccine market include:

• Technological Advancements: The adoption of advanced technologies such as mRNA and other recent vaccine platforms drives market growth by enhancing vaccine effectiveness and enabling rapid response to emerging health risks.
• Increased Awareness and Demand: Growing awareness of the importance of adult vaccination and the increasing demand for preventive health measures are driving market expansion. Public education and health campaigns are contributing to higher vaccination rates.
• Government Support and Policies: Government support, including funding, subsidies, and updated vaccination guidelines, encourages vaccine development and adoption. Policies aimed at improving public health and disease prevention contribute to market growth.
• Investment in Research and Development: Significant investment in vaccine research and development accelerates innovation and the introduction of new vaccines. Funding from governments, private companies, and research institutions supports market expansion.
• Enhanced Distribution Networks: Improvements in vaccine distribution networks, including logistics and infrastructure, enhance access to and coverage of vaccines. Efficient supply chains facilitate broader vaccine availability.

Challenges in the adult vaccine market include:

• High Development and Production Costs: High costs associated with vaccine development and production can be a barrier to market growth. These costs impact pricing and accessibility, particularly in developing markets and low-income populations.
• Regulatory and Compliance Issues: Navigating complex regulatory requirements and ensuring compliance with varying standards across regions can be challenging. Regulatory hurdles can affect market entry and product availability.
• Vaccine Hesitancy and Acceptance: Vaccine hesitancy and concerns about vaccine safety can hinder market growth. Public perception and misinformation may reduce vaccination rates and affect overall market dynamics.

These drivers and challenges shape the adult vaccine market by influencing growth opportunities and market dynamics. Technological innovations, increased awareness, government support, investment in R&D, and enhanced distribution networks drive growth, while high costs, regulatory challenges, and vaccine hesitancy present barriers. Addressing these factors is essential for success in the adult vaccine market.

List of Adult Vaccine Companies

Companies in the market compete based on product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, adult vaccine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.

Some of the adult vaccine companies profiled in this report include:

• GlaxoSmithKline
• Merck & CO
• Sanofi
• Johnson & Johnson
• Serum institute India
• AstraZeneca
• Novartis

Adult Vaccine by Segment

The study includes a forecast for the global adult vaccine market by technology, vaccine type, end use, and region.

Technology [Analysis by Value from 2019 to 2031]:

• Live Attenuated
• Inactivated
• Subunit
• Toxoid
• Conjugate
• Others

Vaccine Type [Analysis by Value from 2019 to 2031]:

• Monovalent
• Multivalent

End Use [Analysis by Value from 2019 to 2031]:

• Private Healthcare Firms
• Government Hospitals

Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country-Wise Outlook for the Adult Vaccine Market

The adult vaccine market is growing significantly, driven by awareness of the product, improvement in technology, and government-sponsored vaccination initiatives. The United States, China, Germany, India, and Japan are actively engaging in vaccine development, deployment, and policy formulation. The growth of the market is propelled by factors that include population aging, heightened attention on the prevention of infectious diseases, and the quality of vaccine production. This report summarizes the most recent changes in these markets and describes new products and services, regulatory activities, and new market strategies for adult vaccines across geographies.

• United States: The US is the forerunner in the production of adult vaccines, now focusing on mRNA vaccines, combination vaccines, and novel concepts of immunization. There is an increase in the recommended vaccination of adults by the CDC, particularly for influenza, pneumococcal, and shingles vaccines. Vaccine manufacturers are investing in better distribution networks to increase the accessibility of immunization services. Moreover, vaccine development for new infectious diseases is supported by federal money. Activities to promote vaccine utilization among adults include public awareness programs and the use of electronic health records that have strengthened the effort to overcome vaccine hesitancy.
• China: The market for vaccines in China is developing at a rapid pace, aided by government efforts to improve vaccination coverage along with the development of local manufacturing. The National Immunization Program (NIP) has been expanded to incorporate further adult vaccines like those for HPV and pneumococcus. There is also investment towards more complex vaccine systems in China, including vaccines using recombinant technology and mRNA vaccines. Further, there is stricter regulation of vaccine production to enhance quality and safety as well as increase self-sufficiency in vaccine production and export. This policy thrust is likely to make China an important adult immunization market for Chinese manufacturers to export to.
• Germany: The public health measures being implemented and biotechnology industry advancements are greatly aiding Germany’s adult vaccine market. The adult vaccination programs related to flu, COVID-19, and RSV have had greater government support. Academic and industry partnerships for the development of next generation vaccines, including those based on individual immunization, are also increasing. Vaccine registration and patient interface in the healthcare system help improve overall immunization compliance. In addition, Germany continues to be one of the major actors in the European region for the supply and production of adult vaccines and is strategically positioned to secure supply chains for these vaccines. Attempts to build trust in vaccines through clear and open communication also contribute to the change in the market.
• India: The adult vaccine market in India is changing as a result of increased government initiatives and rising public awareness. There has been an increase in the adoption of vaccines among adults, such as influenza, pneumococcal, and hepatitis, owing to the expansion of immunization programs beyond childhood. India’s biotechnology industry is progressing with vaccine development, as large pharmaceutical companies are producing low-cost, high-efficacy vaccines for domestic and international markets. In addition, the government is working on cold chain infrastructure improvements to make vaccines more accessible. The privatization of medicine and the rise of digital health are combining to make vaccine distribution and administration more efficient, increasing immunization rates among adults.
• Japan: The adult vaccine market of Japan is changing with the focus on preventive medicine and the need to address the elderly population. The government has active policies for reimbursing vaccines and has extended the policy for adults to include immunization against influenza, pneumococcal infections, and shingles. Research and development for adjuvant formulation and RNA vaccination are on the rise; Japan is also using artificial intelligence and big data to deploy optimally focused vaccine strategies. Attempts to address targeted education to overcome vaccine hesitancy are contributing a stronger base to adult immunization and ensuring the growth of the market in the long run.

Features of this Global Adult Vaccine Market Report

• Market Size Estimates: Adult vaccine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Adult vaccine market size by technology, vaccine type, end use, and region in terms of value ($B).
• Regional Analysis: Adult vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different technologies, vaccine types, end uses, and regions for the adult vaccine market.
• Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the adult vaccine market.

Analysis of the competitive intensity of the industry based on Porter’s Five Forces model. expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M&A, and more.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the adult vaccine market by technology (live attenuated, inactivated, subunit, toxoid, conjugate, and others), vaccine type (monovalent and multivalent), end use (private healthcare firms and government hospitals), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market, and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years, and what has its impact been on the industry?